Results 51 to 60 of about 19,002 (159)
Pharmacology Research &Perspectives, Volume 9, Issue 2, April 2021., 2021 Higher concentrations of anti‐VEGF agents have been observed after ocular administration of nanoparticulate systems in the long‐term in comparison to those of solution formulations of the same agents. The improvements on therapy offered by these nanoparticulate systems have also been evidenced in the higher antiangiogenic properties reported in in ...
María L. Formica +2 more
wiley +1 more source
Clinical Case Reports, Volume 9, Issue 1, Page 61-66, January 2021., 2021 Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonecrosis of the jaw. Multidisciplinary team management of these patients should be provided. Abstract Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce ...
Agostino Guida +4 more
wiley +1 more source
Intravitreal Therapy for Diabetic Macular Edema: An Update
Journal of Ophthalmology, Volume 2021, Issue 1, 2021., 2021 Diabetic macular edema (DME) represents a prevalent and disabling eye condition. Despite that DME represents a sight‐threatening condition, it is also among the most accessible to treatment. Many different treatment options including photocoagulation, intravitreal medical treatment (either vascular endothelial growth factor inhibitors or ...
Claudio Furino +4 more
wiley +1 more source
pH of anti-VEGF agents in the human vitreous: low impact of very different formulations
International Journal of Retina and Vitreous, 2017 Background The aim of the study was to measure pH changes of the human vitreous caused by the intravitreal drugs bevacizumab, ranibizumab, aflibercept, and ziv-aflibercept.
Bianka Sobolewska +3 more
doaj +1 more source
Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome [PDF]
Hospital Pharmacy, 2013 The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Jessica N, Lee +2 more
openaire +2 more sources
Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts. [PDF]
PLoS ONE, 2014 The Notch ligand Delta-like 4 (Dll4) is highly expressed in vascular endothelium and has been shown to play a pivotal role in regulating tumor angiogenesis.
Kiersten Marie Miles +12 more
doaj +1 more source
Viability of Primary Human Pigment Epithelium Cells and Muller-Glia Cells after Intravitreal Ziv-Aflibercept and Aflibercept [PDF]
, 2016 Purpose: The aim of this study was to access the safety profiles of 2 fusion proteins with anti-vascular endothelial growth factor action (ziv-aflibercept and aflibercept) on retinal pigment epithelium cells and Muller-Glia cells in culture by assessing ...
Haritoglou, Christos +12 more
core +1 more source
Drug-induced immune-mediated thrombocytopenia due to bevacizumab-FOLFOX therapy: a case report [PDF]
Kosin Medical Journal, 2023 Drug-induced immune thrombocytopenia (DITP) is a very rare disease, with an estimated annual incidence of 10 cases per million. Oxaliplatin and irinotecan are widely used as chemotherapy for high-risk stage II and III colorectal cancer, and DITP has been
Minna Kim, Jong Hoon Lee, Jong Yoon Lee
doaj +1 more source
Cancer Medicine, Volume 9, Issue 4, Page 1485-1494, February 2020., 2020 Mismatch repair proficient colorectal cancer has been refractory to single‐agent programmed cell death protein 1 inhibitor therapy. Colon GVAX is an allogeneic, whole‐cell, granulocyte‐macrophage colony‐stimulating factor‐secreting cellular immunotherapy that induces T‐cell immunity against tumor‐associated antigens and has previously been studied in ...
Mark Yarchoan +19 more
wiley +1 more source
Frontiers in Oncology, 2023 ObjectiveIt remains unclear what the best second-line treatment is for patients with small-cell lung cancer sensitive to previous platinum-based chemotherapy.MethodsWe systematically screened randomized controlled trials from several online databases ...
Hekai Shi +6 more
doaj +1 more source